Composition for promoting bone health and its application

By using the composition of lactate calcium, colostrum alkaline protein and Bifidobacterium long subspecies i772 bacterial agent, the utilization rate of calcium is improved, the problem of insufficient calcium conversion in the prior art is solved, and osteoporosis is significantly improved Symptoms, providing a stable and convenient bone health promotion program.

CN118749660BActive Publication Date: 2024-11-15SIPING JUNLEBAO DAIRY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411241407.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-05
Publication Date
2024-11-15
Estimated Expiration
2044-09-05

AI Technical Summary

Technical Problem

Existing bone health preparations cannot effectively convert the absorbed calcium into calcium in the bones, resulting in strong bones and insufficient growth, and cannot effectively promote bone health.

Method used

Using a composition containing lactate calcium, colostrum alkaline protein and Bifidobacterium long subspecies i772 bacteria agent, the conversion rate of calcium in the blood is increased through the action of probiotics and the actual utilization rate of calcium, and is used to prepare and promote bones. Healthy probiotic products, dairy products or health foods.

Benefits of technology

It significantly improved the bone density, bone volume fraction and trabecular thickness in the osteoporosis model of female rats, significantly reduced the trabecular spacing, and the inactivated bacterial agent has good stability, and will not produce post-fermentation and reduce the acid. It's troublesome to use medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
Patent Text Reader

Abstract

The present invention discloses a composition for promoting bone health and its application, and belongs to the field of microbial engineering. Wherein, the composition comprises milk calcium, colostrum basic protein and Bifidobacterium longum subspecies longum i772 bacterial agent. The composition for promoting bone health provided by the present invention, while supplementing calcium, improves the conversion rate of calcium in blood into calcium in bones through the action of probiotics, improves the actual utilization rate of calcium, can effectively promote bone health, and according to experimental data, the composition can significantly improve the bone density, bone volume fraction and trabecular thickness of rats, and significantly reduces the trabecular spacing of rats.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of microbial engineering, and relates to a composition comprising Bifidobacterium longum subspecies longum i772, in particular to a composition for promoting bone health and an application thereof. Background Art

[0002] In recent years, bone health issues have become increasingly prominent, and the corresponding medical treatment and care have consumed a lot of manpower, material resources, and financial resources, causing a heavy burden on families and society. Existing bone health preparations are insufficient in efficacy and function, and how to effectively promote bone health has become a major issue.

[0003] Conventional calcium supplementation methods have always focused on increasing calcium intake and optimizing the form of calcium, thereby facilitating the body's absorption of calcium. However, there is controversy over whether calcium can be truly used by the body for bone growth and bone strengthening after absorption. Some scholars believe that calcium absorption only increases the concentration of calcium in the blood to prevent calcium loss in the bones, but does not promote bone strength and growth. While increasing calcium supplementation and absorption, how to convert the absorbed calcium into calcium in the bones is the key to the preparation of preparations that promote bone health. Summary of the invention

[0004] The purpose of the present invention is to provide a composition for promoting bone health and its application, so as to solve the problem that the current conventional calcium supplementation methods cannot convert the absorbed calcium into calcium in the bones, and thus cannot promote bone health well.

[0005] A composition for promoting bone health, comprising milk calcium, colostrum basic protein and Bifidobacterium longum subspecies longum i772 bacterial agent.

[0006] Among them, Bifidobacterium longum subspecies longum i772 (Latin name: Bifidobacterium longumsubsp.longum ), the strain was deposited in the General Microbiological Center of China Microbiological Culture Collection Committee on May 20, 2020, with the deposit address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCCNO.19856. The strain was first disclosed in the Chinese invention patent with publication number CN112458015B and the name "Bifidobacterium longum subsp. longum i772, its isolation and purification method and application".

[0007] As a limitation, the weight ratio of the milk calcium, colostrum alkaline protein and Bifidobacterium longum subspecies longum i772 bacterial agent is 110-150:10-20:0.2-0.5.

[0008] As another limitation, the Bifidobacterium longum subspecies longum i772 bacterial agent is a live bacterial agent and / or an inactivated bacterial agent.

[0009] As a further limitation, the amount of live bacteria of Bifidobacterium longum subspecies longum i772 or the amount of live bacteria before inactivation thereof is 1×10 8 -4x10 11 CFU / g.

[0010] The inactivated bacteria agent is prepared by inoculating Bifidobacterium longum subspecies longum i772 in a fermentation broth containing skim milk, and undergoing fermentation, centrifugation, inactivation and freeze-drying. The inactivation condition is to maintain the temperature at 90-98°C for 20-40 minutes, and the amount of live bacteria after inactivation is less than 3000 CFU / g.

[0011] The present invention also provides the use of the above composition in preparing probiotic products, dairy products or health foods that promote bone health.

[0012] The present invention also provides milk, comprising the above composition for promoting bone health.

[0013] The present invention also provides a milk powder comprising the above composition for promoting bone health.

[0014] The present invention also provides a health food comprising the above composition for promoting bone health.

[0015] Due to the adoption of the above technical solution, the present invention has the following technical advances compared with the prior art:

[0016] ① The composition for promoting bone health provided by the present invention can improve the conversion rate of calcium in the blood into calcium in the bones through the action of probiotics while supplementing calcium, improve the actual utilization rate of calcium, and effectively promote bone health. According to experimental data, the composition can significantly increase the bone density, bone volume fraction and trabecular thickness in the osteoporosis model of female rats, and significantly reduce the trabecular spacing in the osteoporosis model of female rats;

[0017] ② The composition for promoting bone health provided by the present invention can effectively improve osteoporosis even if the Bifidobacterium longum subspecies longum i772 bacterial agent is an inactivated bacterial agent, and the inactivated bacterial agent has good stability and will not produce post-acid problems after fermentation, and there is no need to consider the maintenance of the number of live bacteria;

[0018] ③ The composition for promoting bone health provided by the present invention contains strains that have an intestinal colonization effect and can continuously exert its effect of promoting bone health in the intestine, thereby reducing the trouble of daily medication. DETAILED DESCRIPTION

[0019] The present invention is further described in detail below by specific examples. It should be understood that the described examples are only used to explain the present invention, and are not intended to limit the present invention.

[0020] Unless otherwise specified, the experimental methods used in the following examples are conventional methods in the art.

[0021] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0022] In the following embodiments:

[0023] Bifidobacterium longum subspecies longum i772, the strain was deposited in the China General Microbiological Culture Collection Center on May 20, 2020, with the deposit number CGMCC NO.19856, and the Latin name is Bifidobacterium longum subsp.longum ;

[0024] Bifidobacterium longum subsp. longum JM-0847, which is deposited in the strain collection laboratory of the applicant and can be obtained through purchase or other channels;

[0025] Bifidobacterium longum subsp. longum JM-1107, the bacterial strain is deposited in the strain collection laboratory of the applicant and can be obtained through purchase and other channels.

[0026] Example 1

[0027] This embodiment provides a composition for promoting bone health, which comprises 792 g of milk calcium, 60 g of colostrum alkaline protein and 3 g of Bifidobacterium longum subspecies i772 live bacterial agent (weight ratio is 132:10:0.5), wherein the amount of live bacteria in the Bifidobacterium longum subspecies i772 live bacterial agent is 3.3×10 11 CFU / g.

[0028] Example 2

[0029] This embodiment provides milk, to which 60.1 kg of a composition for promoting bone health is added (the addition amount is 6.01 wt%), wherein the composition comprises 55 kg of milk calcium, 5 kg of colostrum alkaline protein and 0.1 kg of a live bacterial agent of Bifidobacterium longum subspecies i772 (the weight ratio is 110:10:0.2), and the live bacterial amount of the live bacterial agent of Bifidobacterium longum subspecies i772 is 1×10 8 CFU / g.

[0030] Example 3

[0031] This embodiment provides a milk powder, wherein 34.1 g of a composition for promoting bone health is added to 965.9 g of the milk powder (the addition amount is 3.41 wt%), and the composition comprises 30 g of milk calcium, 4 g of colostrum alkaline protein and 0.1 g of a live bacterial agent of Bifidobacterium longum subspecies i772 (the weight ratio is 150:20:0.5), wherein the live bacterial amount of the live bacterial agent of Bifidobacterium longum subspecies i772 is 4×10 11CFU / g.

[0032] Example 4

[0033] This embodiment provides a composition for promoting bone health, which comprises 792g of milk calcium, 60g of colostrum alkaline protein and 3g of inactivated bacteria agent of Bifidobacterium longum subspecies i772 (weight ratio is 132:10:0.5), wherein the amount of live bacteria of Bifidobacterium longum subspecies i772 before inactivation is 3.3x10 11 CFU / g, the amount of live bacteria after inactivation is less than 3000 CFU / g.

[0034] Example 5

[0035] This embodiment provides a health food, to which 626g of a composition for promoting bone health is added (the addition amount is 6.26wt%), the composition comprising 550g of milk calcium, 75g of colostrum alkaline protein and 1g of a sterilizing agent for Bifidobacterium longum subspecies i772 (the weight ratio is 110:15:0.2), wherein the amount of live bacteria of Bifidobacterium longum subspecies i772 before inactivation is 1x10 8 CFU / g, the amount of live bacteria after inactivation is less than 3000 CFU / g.

[0036] Example 6

[0037] This embodiment provides a milk powder, to which 42.6 g of a composition for promoting bone health is added (the addition amount is 4.26 wt %), the composition comprising 37.5 g of milk calcium, 5 g of colostrum alkaline protein and 0.1 g of a sterilizing agent for Bifidobacterium longum subspecies i772 (the weight ratio is 150:20:0.4), wherein the amount of live bacteria of Bifidobacterium longum subspecies i772 before inactivation is 4×10 11 CFU / g, the amount of live bacteria after inactivation is less than 3000 CFU / g.

[0038] Example 7

[0039] This embodiment provides an application of a composition for promoting bone health, wherein the composition is used to improve osteoporosis, and a control experiment is provided, which specifically includes the following steps:

[0040] S1. Preparation of experimental materials

[0041] 1) Sample preparation

[0042] Sample 1: Take a probiotic containing live bacteria of Bifidobacterium longum subspecies longum i772 (live bacteria quantity is 1.6x10 10 CFU / g) was prepared into a solution with normal saline and recorded as active i772;

[0043] Sample 2: Take the probiotic preparation of inactivated bacteria of Bifidobacterium longum subspecies longum i772 (the amount of live bacteria before sterilization is 1.6x10 10 CFU / g, the amount of viable bacteria after sterilization is less than 3000 CFU / g), and it is prepared into a solution with normal saline and recorded as inactivated i772;

[0044] Sample 3: Take the probiotic preparation containing live bacteria of Bifidobacterium longum subspecies longum JM-0847 (live bacteria quantity is 1.6x10 10 CFU / g) was prepared into a solution with normal saline and recorded as activity 0847;

[0045] Sample 4: Take the probiotic agent of inactivated bacteria of Bifidobacterium longum subspecies longum JM-0847 (the amount of live bacteria before sterilization is 1.6x10 10 CFU / g, the amount of viable bacteria after sterilization is less than 3000 CFU / g), and it is prepared into a solution with normal saline and recorded as inactivated 0847;

[0046] Sample 5: Take the probiotic preparation containing live bacteria of Bifidobacterium longum subspecies longum JM-1107 (live bacteria quantity is 1.6x10 10 CFU / g) was prepared into a solution with normal saline and recorded as activity 1107;

[0047] Sample 6: Take the probiotic agent of inactivated bacteria of Bifidobacterium longum subspecies longum JM-1107 (the amount of live bacteria before sterilization is 1.6x10 10 CFU / g, the amount of viable bacteria after sterilization is less than 3000 CFU / g), and it is prepared into a solution with normal saline and recorded as inactivated 1107;

[0048] Sample 7: The composition in Example 1 was prepared into a solution with physiological saline, which was recorded as active i772 composition;

[0049] Sample 8: The composition in Example 4 was prepared into a solution with physiological saline, which was recorded as the inactivated i772 composition;

[0050] Sample 9: Replace the Bifidobacterium longum subspecies longum i772 live bacterial agent in Sample 7 with JM-1107 live bacterial agent (the live bacterial amount is also 3.3x10 11 CFU / g), the dosage of other components remained unchanged, and was recorded as active 1107 composition;

[0051] Anesthetic (5% chloral hydrate): Dissolve 5 g of chloral hydrate in about 60 ml of normal saline, add normal saline to make up to 100 ml, and store at room temperature away from light.

[0052] 2) Experimental animals

[0053] Sprague Dawley rats (SD rats), female, 10-12 weeks old.

[0054] The experimental animals were provided by Sbefor (Suzhou) Biological Co., Ltd. (China), certificate: SCXK(Su)2022-0006.

[0055] 3) Instruments, consumables and reagents

[0056] Disposable 5 ml syringe (Shanghai Kangdeli, China), electronic analytical balance Precisa12A (Plissex, Switzerland), depyrogenation ultrapure water system Millipo3150 (Millipore, USA), three-section rat gavage needle (Zhongke Life Science, China), electric constant temperature water bath HW-SY11-K P2 (Beijing Changfeng Instrument Co., Ltd., China), 1.5 ml centrifuge tube (Wuxi Nice Life Science Co., Ltd., China), ultra-low temperature refrigerator Sanyo-382AT (Sanyo Company, Japan), 6-0 absorbable suture (Shanghai Jinhuan Medical Instrument Co., Ltd., China), Micro-CT scanner Skyscan1276 (Bruker, USA).

[0057] 0.9% sodium chloride injection (L222042401, Sichuan Kelun Pharmaceutical Co., Ltd., China), chloral hydrate (C104202-250g, Shanghai Aladdin Biochemical Technology Co., Ltd., China), paraformaldehyde fixative (G1101, Wuhan Saiweier Biotechnology Co., Ltd., China), and alendronate sodium (A115345-25g, Shanghai Aladdin Biochemical Technology Co., Ltd., China).

[0058] S2. Experimental methods

[0059] 1) Animal grouping and osteoporosis modeling

[0060] After 7 days of adaptive feeding, 120 SD rats were divided into 12 groups: blank control group, model control group, positive drug group, inactivated fungicide group (including inactivated i772 group, inactivated 0847 group, inactivated 1107 group), active fungicide group (including active i772 group, active 0847 group, active 1107 group), inactivated control group (including inactivated i772 combination group), experimental group (including active i772 combination group, active 1107 combination group), 10 rats in each group.

[0061] Except for the blank control group, all SD rats underwent ovariectomy: after anesthesia, the ventral skin was prepared, hair removed, and disinfected. A 2-cm incision was made in the midline of the abdomen using sterile surgical scissors to separate and expose the ovaries, and then the ovaries were removed after ligation with sutures. After the operation, the uterus was returned to the abdominal cavity, the muscles and skin were sutured layer by layer, and the wound was disinfected with iodine and placed on a heating pad for normal feeding after waking up.

[0062] The blank control group underwent sham surgery: only anesthesia was performed to make the incision, and the ovaries were exposed but not ligated and removed. The ovaries were placed back into the abdominal cavity and the wounds were sutured. The mice were fed normally after waking up.

[0063] 2) Sample administration by intragastric gavage

[0064] The SD rats in each group were gavaged daily starting the day after surgery. The SD rats in the blank control group and the model control group were given an equal volume of normal saline daily; the SD rats in the positive drug group were given the same volume of 40 mg / kg alendronate sodium (solvent was normal saline) once a day for 28 consecutive days.

[0065] The SD rats in the active bacteria group were gavaged with equal volumes of active i772, active 0847, or active 1107 daily (the amount of live bacteria ingested by the rats was 1.135 x 10 8 CFU, the dosage is converted to human body, which is 5x10 per day 9 CFU), once a day for 28 consecutive days.

[0066] The SD rats in the inactivated bacteria group were given an equal volume of inactivated i772, inactivated 0847 or inactivated 1107 by gavage every day (the amount of inactivated bacteria ingested by the rats was 1.135x10 8 CFU, the dosage is converted to human body, which is 5x10 per day 9 CFU), once a day for 28 consecutive days.

[0067] The SD rats in the experimental group were gavaged with equal volumes of active i772 composition or active 1107 composition daily (daily intake of milk calcium, colostrum alkaline protein and live bacteria of rats were 18 mg, 1.36 mg and 2.27 x 10 7 CFU, the dosage converted to human body, the daily intake is 792mg, 60mg and 1x10 9 CFU), once a day for 28 consecutive days.

[0068] The SD rats in the inactivated control group were intragastrically administered with an equal volume of the inactivated i772 composition daily (the daily intake of milk calcium, colostrum alkaline protein and inactivated bacteria in rats was 18 mg, 1.36 mg and 2.27 x 10 7 CFU, the dosage converted to human body, the daily intake is 792mg, 60mg and 1x10 9 CFU), once a day for 28 consecutive days.

[0069] 3) Femoral sampling and scanning

[0070] 24 hours after the last intragastric administration, the femurs of SD rats in each group were taken, the muscles and connective tissues around the femurs were removed, and the femurs were fixed and preserved in paraformaldehyde fixative.

[0071] The lower femur was taken out from the fixative, rinsed with PBS buffer for 3 times, wiped dry, and wrapped with a sealing film to obtain the lower femur sample;

[0072] Start the Micro-CT scanner Skyscan1276 program, initialize and preheat, open the sample chamber, put the lower femur sample along the length direction of the semi-cylindrical column of the sample chamber, raise the position of the lower femur sample with the help of foam and paper to ensure that it is at the center of the semicircle, and fix it with 3M tape, close the sample chamber door, and scan with a scanning resolution of 18 μm;

[0073] After scanning, CTvox software was used for 3D reconstruction, and the femoral morphology was exported. CTAn software was used to analyze the bone density, bone tissue volume / total tissue volume (bone volume fraction), trabecular thickness, and trabecular separation / spacing in the femoral condyle area. The results are shown in Table 1. The meanings of each data are as follows:

[0074] BMD: bone density, which reflects the condition of bones. A decrease in the index indicates osteoporosis.

[0075] BV / TV: Bone volume fraction, which reflects bone metabolism. A decrease in the index means that bone decomposition is greater than synthesis, and bone mass decreases.

[0076] Tb.Th: trabecular thickness, which reflects the morphological structure of bones. A decrease in the index indicates that the pores in the bone become larger.

[0077] Tb.Sp: Trabecular spacing, this index reflects the morphological structure of bones. An increase in the index means more pores in the bone.

[0078] S3. Experimental Results

[0079] Table 1 Experimental results

[0080]

[0081] Note: * indicates that there is a significant difference with the model control group, p < 0.05; *** indicates that there is a very significant difference with the model control group, p < 0.001;

[0082] Different lowercase letters indicate significant differences among experimental groups, p < 0.05.

[0083] As shown in Table 1, the probiotics prepared from the live bacteria or inactivated bacteria of Bifidobacterium longum subspecies longum i772 all have the effect of improving osteoporosis, and compared with JM-0847 and JM-1107 of the same genus and species, the effect of i772 on improving osteoporosis is significantly different. Specifically, compared with the model control group, the live bacteria or inactivated bacteria of i772 can significantly inhibit the decrease of bone density, bone volume fraction and trabecular thickness in the rat osteoporosis model, and significantly increase the trabecular spacing in the rat osteoporosis model; while compared with the model control group, the live bacteria or inactivated bacteria of 0847 and the inactivated bacteria of 1107 can not significantly inhibit the decrease of bone density, bone volume fraction and trabecular thickness in the rat osteoporosis model, nor can they significantly increase the trabecular spacing. Compared with groups 0847 and 1107, group i772 showed significant differences in inhibiting the decrease of bone density, bone volume fraction and trabecular thickness in the rat osteoporosis model, and increasing the trabecular spacing in the rat osteoporosis model.

[0084] At the same time, it can also be seen that the compositions containing the live bacteria of Bifidobacterium longum subspecies longum i772 or its inactivated bacteria have the effect of improving osteoporosis, and compared with the composition containing the live bacteria of JM-1107 of the same genus and species, the effect of improving osteoporosis is significantly different. Specifically, compared with the 1107 live bacteria composition, the i772 composition has significant differences in inhibiting the decrease of bone density, bone volume fraction and trabecular thickness in the rat osteoporosis model, and increasing the trabecular spacing in the rat osteoporosis model.

Claims

1. A composition for promoting bone health, characterized in that: The composition consists of milk calcium, colostrum alkaline protein and Bifidobacterium longum subspecies longum i772 bacterial agent in a weight ratio of 110-150:10-20:0.2-0.

5.

2. The composition for promoting bone health according to claim 1, characterized in that: The Bifidobacterium longum subspecies longum i772 bacterial agent is a live bacterial agent or an inactivated bacterial agent.

3. The composition for promoting bone health according to claim 2, characterized in that: The live bacterial count of Bifidobacterium longum subspecies longum i772 or the live bacterial count before inactivation is 1×10 8 -4x10 11 CFU / g.

4. Use of the composition according to any one of claims 1 to 3 in the preparation of probiotic products, dairy products or health foods that promote bone health.

5. A milk, characterized in that: A composition for promoting bone health comprising the composition described in any one of claims 1 to 3.

6. A milk powder, characterized in that: A composition for promoting bone health comprising the composition described in any one of claims 1 to 3.

7. A health food, characterized in that: A composition for promoting bone health comprising the composition described in any one of claims 1 to 3.